Literature DB >> 27318091

Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer.

Zhongxing Liang1, Xuehai Bian2, Hyunsuk Shim3.   

Abstract

Triple negative breast tumors don't respond to Tamoxifen and Herceptin, two of the most effective medications for treating breast cancer. Additionally, triple negative breast cancer (TNBC) intrinsically resists or will eventually acquire resistance to chemotherapy. The purpose of this study is to understand better the molecular basis of TNBC as well as develop new therapeutic strategies against it. Here, we analyzed miRNA-206 expression levels in breast cancer cell lines and tissues. In addition, we investigated whether miR-206 mimics inhibited TNBC tumor invasion and angiogenesis. The results showed that miR-206 was downregulated in TNBC compared to non-TNBC cell lines and tissues. Additionally, the decreased levels of miR-206 were inversely consistent with expression levels of VEGF. Furthermore, the forced expression of miR-206 in the mimic-transfected TNBC cells downregulated VEGF, MAPK3, and SOX9 expression levels. The miR-206 mimics inhibited TNBC breast cell invasion and angiogenesis. These findings demonstrate for the first time the involvement of miRNA-206 in TNBC invasion and angiogenesis and suggest that miR-206 may be an efficient agent for therapy of TNBC.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Invasion; MicroRNA; Triple negative breast cancer; VEGF

Mesh:

Substances:

Year:  2016        PMID: 27318091      PMCID: PMC4955785          DOI: 10.1016/j.bbrc.2016.06.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Radioresistance in carcinoma of the breast.

Authors:  J K A Jameel; V S R Rao; L Cawkwell; P J Drew
Journal:  Breast       Date:  2004-12       Impact factor: 4.380

3.  The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.

Authors:  Katharine Kirkpatrick; William Ogunkolade; A Elkak; Stephen Bustin; Paul Jenkins; Margaret Ghilchik; Kefah Mokbel
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

4.  MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Authors:  E Missiaglia; C J Shepherd; S Patel; K Thway; G Pierron; K Pritchard-Jones; M Renard; R Sciot; P Rao; O Oberlin; O Delattre; J Shipley
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.

Authors:  Zhongxing Liang; Joann Brooks; Margaret Willard; Ke Liang; Younghyoun Yoon; Seunghee Kang; Hyunsuk Shim
Journal:  Biochem Biophys Res Commun       Date:  2007-06-04       Impact factor: 3.575

7.  Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.

Authors:  Akiko Sasaki; Yuko Tsunoda; Mayumi Tsuji; Yuko Udaka; Hideto Oyamada; Hiromichi Tsuchiya; Katsuji Oguchi
Journal:  Anticancer Res       Date:  2014-09       Impact factor: 2.480

8.  Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer.

Authors:  Qi Yang; Chao Zhang; Bo Huang; Huiyan Li; Rong Zhang; Yuxin Huang; Jingjie Wang
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 2.566

Review 9.  What is triple-negative breast cancer?

Authors:  William J Irvin; Lisa A Carey
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

10.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.

Authors:  Zhongxing Liang; Hui Wu; James Xia; Yuhua Li; Yawei Zhang; Ke Huang; Nicholas Wagar; Younghyoun Yoon; Heidi T Cho; Stefania Scala; Hyunsuk Shim
Journal:  Biochem Pharmacol       Date:  2009-10-31       Impact factor: 6.100

View more
  27 in total

Review 1.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

2.  MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC.

Authors:  Bisheng Huang; Wei Zhai; Guanghui Hu; Chi Huang; Tiancheng Xie; Jingwei Zhang; Yunfei Xu
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.

Authors:  Eric Salgado; Xuehai Bian; Amber Feng; Hyunsuk Shim; Zhongxing Liang
Journal:  Biochem Biophys Res Commun       Date:  2018-06-23       Impact factor: 3.575

Review 4.  SOX9: The master regulator of cell fate in breast cancer.

Authors:  Samir Jana; B Madhu Krishna; Jyotsana Singhal; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2020-01-03       Impact factor: 6.100

5.  Overexpression of suppressive microRNAs, miR-30a and miR-200c are associated with improved survival of breast cancer patients.

Authors:  Tsutomu Kawaguchi; Li Yan; Qianya Qi; Xuan Peng; Emmanuel M Gabriel; Jessica Young; Song Liu; Kazuaki Takabe
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

6.  MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2.

Authors:  Wentao Tang; Pingping Xu; Hong Wang; Zhengchuan Niu; Dexiang Zhu; Qi Lin; Liming Tang; Li Ren
Journal:  Onco Targets Ther       Date:  2018-04-24       Impact factor: 4.147

7.  Diversity and signature of small RNA in different bodily fluids using next generation sequencing.

Authors:  Mohamed El-Mogy; Bernard Lam; Taha A Haj-Ahmad; Shannon McGowan; Darrick Yu; Lucas Nosal; Nezar Rghei; Pam Roberts; Yousef Haj-Ahmad
Journal:  BMC Genomics       Date:  2018-05-29       Impact factor: 3.969

Review 8.  The regulatory role of microRNAs in angiogenesis-related diseases.

Authors:  Li-Li Sun; Wen-Dong Li; Feng-Rui Lei; Xiao-Qiang Li
Journal:  J Cell Mol Med       Date:  2018-06-29       Impact factor: 5.310

9.  SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.

Authors:  Xiaodong Yuan; Jun Li; Cédric Coulouarn; Tao Lin; Laurent Sulpice; Damien Bergeat; Carolina De La Torre; Roman Liebe; Norbert Gretz; Matthias P A Ebert; Steven Dooley; Hong-Lei Weng
Journal:  Br J Cancer       Date:  2018-11-13       Impact factor: 7.640

Review 10.  BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer.

Authors:  JaeIn Park; Jae-Hyun Jang; Geun-Soo Park; Yunro Chung; Hye Jin You; Jae-Hong Kim
Journal:  BMB Rep       Date:  2018-08       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.